What Is KLOW Peptide? A Plain-English Overview

In plain English

What is KLOW peptide? It is four separate research peptides dissolved together in one vial. The four are KPV, GHK-Cu, BPC-157, and TB-500. Each has its own published research record. None of them is FDA-approved. The combination has never been tested in a controlled study.

Here is the one-sentence version of each component's research role. KPV: a small anti-inflammatory peptide that quiets the molecular switch driving gut inflammation. GHK-Cu: a copper-bearing peptide that promotes collagen and affects a broad range of gene activity in skin cells. BPC-157: a synthetic peptide studied mostly in rats for tendon and tissue repair. TB-500: a small fragment of a larger protein linked to wound closure and cell movement, where most of the strong data come from the full-length protein, not this fragment.

KLOW is not a weight-loss compound. It is not a GLP-1 peptide. It is a research-only co-formulation used in laboratory settings, and the pages in this dossier document what the published research on each component has actually found.

What is KLOW peptide made of?

KLOW is a co-formulation: multiple distinct compounds co-dissolved at fixed mass ratios in a single lyophilized vial. The most widely listed research composition is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. The peptides remain separate molecules after reconstitution; they do not react to form a new compound.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper(II) complex, CAS 89030-95-5, 402.92 Da) makes up about 62.5% of the canonical vial by mass. It is a naturally occurring tripeptide chelated to a copper ion, first isolated from human plasma in 1973. It is the reason reconstituted KLOW is blue-green: the copper(II) ion gives GHK-Cu that characteristic color, and at half the vial's mass it dominates the appearance of the solution.

KPV (Lys-Pro-Val, CAS 67727-97-3, 342.44 Da) is the anti-inflammatory arm — the C-terminal fragment of alpha-MSH, a 13-residue anti-inflammatory signaling peptide. It makes up 10 mg of the vial but represents, in the view of this dossier, the most mechanistically specific component: its documented NF-kappaB suppression and PepT1-mediated gut-epithelium uptake distinguish it from everything else in the stack ^[1].

BPC-157 (GEPPPGKPADDAGLV, CAS 137525-51-0, 1419.53 Da) is 10 mg of the vial — the largest molecule by molecular weight despite being a small share by mass. It is a 15-amino-acid synthetic peptide derived from a gastric-juice protein, studied in rodent tissue-repair models including transected Achilles tendon ^[2].

TB-500 (Ac-LKKTETQ, 889.02 Da) is the remaining 10 mg — a synthetic heptapeptide corresponding to the actin-binding motif of thymosin beta-4. Most of the wound-healing and cell-migration data cited for this arm come from the full-length 43-amino-acid native protein, not from this shorter fragment ^[3].

What does KLOW do — and what is the combination gap?

Each component's research record supports a different mechanistic story. KPV suppresses NF-kappaB and MAPK signaling at nanomolar concentrations and is taken up into inflamed gut cells by the PepT1 transporter ^[1]. GHK-Cu stimulates collagen synthesis and modulates a broad transcriptomic program in fibroblasts toward matrix remodeling, antioxidant defense, and DNA repair ^[4][5]. BPC-157 activates the VEGFR2 angiogenic pathway and has shown tissue-repair activity across a range of rodent injury models ^[2]. The TB-500 fragment sequesters G-actin, a step mechanistically linked to cell migration and wound closure.

The combination rationale — that these four arms address cytokine suppression, matrix remodeling, vascular supply, and cytoskeletal mobility as complementary steps of the same tissue-repair cascade — is a mechanistic hypothesis. It has not been tested in any controlled study of the four-peptide blend. No study has measured whether the combination produces additive, synergistic, or antagonistic effects relative to any component alone.

This is not a minor caveat. It is the central limitation of the KLOW literature — or, more precisely, of the KLOW non-literature. The published record for the blend is empty. Everything attributed to 'KLOW' in this dossier is attributed through the component it belongs to.

How is KLOW different from other peptide blends?

KLOW's closest relative is the GLOW blend, which contains GHK-Cu, BPC-157, and TB-500. KLOW adds KPV as the fourth component. The KPV arm is the defining difference: NF-kappaB / MAPK suppression via PepT1-mediated gut-epithelium uptake is a pathway that none of the GLOW components targets ^[1]. Whether this addition changes clinical outcomes — in what populations, for what indications — is the question no controlled study has yet answered.

KLOW is also distinct from WOLVERINE, a research-community blend that combines BPC-157 and TB-500 in a two-component formulation. KLOW and WOLVERINE share two of their four and two components respectively, but KLOW adds the copper-peptide GHK-Cu arm and the anti-inflammatory KPV arm.

None of these blends — KLOW, GLOW, or WOLVERINE — has been tested in a controlled clinical trial. All are research-only co-formulations used in laboratory settings. The distinctions above are compositional; they do not imply outcome differences that any study has measured.

KLOW research: status and compliance

KLOW is not FDA-approved. None of its four components is approved for human use as an individual compound. BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review. TB-500, as the synthetic fragment of thymosin beta-4, implicates the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition ^[7].

Human evidence for the component compounds individually is limited: GHK-Cu has substantial topical cosmetic and wound-healing data; BPC-157 has a 2025 IV safety pilot in two adults reporting no adverse events ^[6] and a small number of case series; thymosin beta-4 (not the TB-500 fragment) has early-phase trials; KPV human data are restricted to formulation pilots and its IBD-drug lineage. The combination blend has no human data at all.

For a detailed account of what people report — including the specific cautions for athletes, people with cancer, and people with copper-metabolism or autoimmune conditions — the effects page carries the full safety context.